101 related articles for article (PubMed ID: 11681590)
41. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders.
Luedtkea RR; Mach RH
Curr Pharm Des; 2003; 9(8):643-71. PubMed ID: 12570797
[TBL] [Abstract][Full Text] [Related]
42. Profiling of behavioral effects evoked by ketamine and the role of 5HT
Galvanho JP; Manhães AC; Carvalho-Nogueira ACC; Silva JM; Filgueiras CC; Abreu-Villaça Y
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Mar; 97():109775. PubMed ID: 31676464
[TBL] [Abstract][Full Text] [Related]
43. Combined use of mutant mice and classical pharmacology to characterise receptor functions: the case of dopamine D2 and D3 receptors.
Depoortere R
Psychopharmacology (Berl); 1999 Nov; 147(1):20-1. PubMed ID: 10591860
[No Abstract] [Full Text] [Related]
44. Modulation of drug-induced sensitization processes by endogenous opioid systems.
Spanagel R
Behav Brain Res; 1995 Sep; 70(1):37-49. PubMed ID: 8519427
[TBL] [Abstract][Full Text] [Related]
45. There is more to dopamine than just pleasure. Commentary on Volkow et al. 'Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies'.
Lingford-Hughes A
Behav Pharmacol; 2002 Sep; 13(5-6):367-70. PubMed ID: 12394412
[No Abstract] [Full Text] [Related]
46. Cognitive control and the dopamine D₂-like receptor: a dimensional understanding of addiction.
Groman SM; Jentsch JD
Depress Anxiety; 2012 Apr; 29(4):295-306. PubMed ID: 22147558
[TBL] [Abstract][Full Text] [Related]
47. Effects of Pro-Gly-Pro tripeptide on the dopamine system.
Meshavkin VK; Batishcheva EY; Kost NV; Sokolov OY; Trufanova AV; Samonina GE
Bull Exp Biol Med; 2011 Aug; 151(4):429-31. PubMed ID: 22448358
[TBL] [Abstract][Full Text] [Related]
48. Dopaminergic mechanisms in idiopathic and drug-induced psychoses.
Lieberman JA; Kinon BJ; Loebel AD
Schizophr Bull; 1990; 16(1):97-110. PubMed ID: 2185538
[TBL] [Abstract][Full Text] [Related]
49. Neurobiology of cocaine abuse.
Woolverton WL; Johnson KM
Trends Pharmacol Sci; 1992 May; 13(5):193-200. PubMed ID: 1604712
[TBL] [Abstract][Full Text] [Related]
50. The Role of Dopamine D3 Receptors in Tobacco Use Disorder: A Synthesis of the Preclinical and Clinical Literature.
Butler K; Le Foll B; Di Ciano P
Curr Top Behav Neurosci; 2023; 60():203-228. PubMed ID: 36173599
[TBL] [Abstract][Full Text] [Related]
51. Dopamine receptor hetero-oligomerization: a hypothesis for behavioral sensitization to psychostimulants.
Tsai SJ; Hong CJ
Med Hypotheses; 2003 Jul; 61(1):18-20. PubMed ID: 12781635
[TBL] [Abstract][Full Text] [Related]
52. Self-injection of apomorphine in the rat: positive reinforcement by a dopamine receptor stimulant.
Baxter BL; Gluckman MI; Stein L; Scerni RA
Pharmacol Biochem Behav; 1974 May; 2(3):387-91. PubMed ID: 4858099
[No Abstract] [Full Text] [Related]
53. Homologies and differences in the action of drugs of abuse and a conventional reinforcer (food) on dopamine transmission: an interpretative framework of the mechanism of drug dependence.
Di Chiara G; Tanda G; Cadoni C; Acquas E; Bassareo V; Carboni E
Adv Pharmacol; 1998; 42():983-7. PubMed ID: 9328062
[No Abstract] [Full Text] [Related]
54. Conceptualizing Addiction From an Osteopathic Perspective: Dopamine Homeostasis.
Baron D; Blum K; Chen A; Gold M; Badgaiyan RD
J Am Osteopath Assoc; 2018 Feb; 118(2):115-118. PubMed ID: 29379966
[TBL] [Abstract][Full Text] [Related]
55. [Conditional stimulus or conditional reinforcer? The current trend in the renewed study on drug dependence].
Hironaka N
Nihon Yakurigaku Zasshi; 2006 Oct; 128(4):2005-6. PubMed ID: 17117530
[No Abstract] [Full Text] [Related]
56. Are we addicted to food?
Del Parigi A; Chen K; Salbe AD; Reiman EM; Tataranni PA
Obes Res; 2003 Apr; 11(4):493-5. PubMed ID: 12690075
[No Abstract] [Full Text] [Related]
57. A Bayesian Observer Model of Drug Craving.
Gu X; Filbey F
JAMA Psychiatry; 2017 Apr; 74(4):419-420. PubMed ID: 28199454
[No Abstract] [Full Text] [Related]
58. Theories and treatment of drug dependency: a neurochemical perspective.
Pakdaman S; Wilcox RE; Miller JD
Curr Mol Pharmacol; 2014; 7(1):52-66. PubMed ID: 25324047
[TBL] [Abstract][Full Text] [Related]
59. Modeling drug dependence behaviors for animal and human studies.
Hughes JR; Bickel WK
Pharmacol Biochem Behav; 1997 Jul; 57(3):413-7. PubMed ID: 9218265
[TBL] [Abstract][Full Text] [Related]
60. Targeting dopamine receptor D3 signalling in inflammation.
Pacheco R
Oncotarget; 2017 Jan; 8(5):7224-7225. PubMed ID: 28086229
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
